Ascendis Pharma (ASND) grants 31,250 new employee share warrants
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Ascendis Pharma A/S granted new equity incentives to employees. On May 12, 2026, the board approved 31,250 warrants for certain employees under Appendix 1a of the Articles of Association. Each warrant allows purchase of one ordinary share at an exercise price of US $237.65, the closing share price on the grant date.
Twenty‑five percent of the warrants vest one year after grant, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service and potential earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,580,593 shares remain available for future grants under the Articles of Association.
Positive
- None.
Negative
- None.
Key Figures
Warrants granted: 31,250 warrants
Exercise price: US $237.65 per share
Remaining warrant capacity: 1,580,593 shares
+2 more
5 metrics
Warrants granted
31,250 warrants
Granted to certain employees on May 12, 2026
Exercise price
US $237.65 per share
Equal to closing price on grant date
Remaining warrant capacity
1,580,593 shares
Warrants available for future grants after this issuance
Initial vesting tranche
25% of warrants
Vest on first anniversary of grant date
Subsequent vesting schedule
75% over 36 months
Vest monthly starting one year after grant, subject to service
Key Terms
Form 6-K, warrants, Articles of Association, exercise price, +1 more
5 terms
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
warrants financial
"granted an aggregate of 31,250 warrants to certain employees of the Company"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Articles of Association regulatory
"under the terms of Appendix 1a to the Company’s Articles of Association"
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
exercise price financial
"has an exercise price equal to US $237.65 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the Warrants will vest on the one year anniversary of the date of grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Ascendis Pharma (ASND) announce in this Form 6-K?
Ascendis Pharma disclosed that its board granted 31,250 new warrants to certain employees. Each warrant gives the right to buy one ordinary share, aligning employee compensation with shareholder value through equity-based incentives governed by the company’s Articles of Association.
What is the exercise price of Ascendis Pharma’s newly granted warrants?
The newly granted warrants have an exercise price of US $237.65 per share. This price equals the closing market price of Ascendis Pharma’s ordinary shares on the May 12, 2026 grant date, tying the option cost directly to the prevailing share value.
How do the Ascendis Pharma employee warrants vest over time?
Twenty-five percent of the warrants vest on the one-year anniversary of the May 12, 2026 grant. The remaining 75% then vest in equal 1/36th monthly installments over the following three years, subject to continued service and potential earlier vesting upon specified exit events.
How many additional Ascendis Pharma warrants remain available for future grants?
After this grant, warrants to subscribe for an additional 1,580,593 Ascendis Pharma shares remain available. These can be granted in the future by the board of directors under the company’s Articles of Association as part of ongoing equity incentive programs.
What corporate document governs the new Ascendis Pharma warrant grants?
The warrants were granted under Appendix 1a of Ascendis Pharma’s Articles of Association. In connection with these grants, the company amended its Articles of Association, which are included as Exhibit 1.1 and incorporated by reference in the Form 6-K.